Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is a tissue biomarker for detection of early Hepatocellular carcinoma in patients with cirrhosis

Journal of Hematology and Oncology

Volumn 5, Issue , 2012, Pages

  Guo, Yantong ^a   Zhao, Jingming ^a   Bi, Jingtao ^a   Wu, Quan ^a   Wang, Xin ^a   Lai, Quanyou ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

Biomarker; Diagnosis; Hepatocellular carcinoma; Mass spectrometry; Proteome; Two dimensional gel electrophoresis

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN K; SSP2215 PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AMINO ACID SEQUENCE; ARTICLE; BLOOD SAMPLING; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER PATIENT; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER SURGERY; MALE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PATHOPHYSIOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

ALPHA-FETOPROTEINS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN K; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROTEOMICS; ROC CURVE; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84863227127     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-5-37     Document Type: Article

References (28)

1. Epidemiology of hepatocellular carcinoma. Bosch FX, Ribes J, Cleries R, Diaz M, Clin Liver Dis 2005 9 191 211 v. 10.1016/j.cld.2004.12.009 15831268
2. Clinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma. Rabe C, Pilz T, Klostermann C, Berna M, Schild HH, Sauerbruch T, Caselmann WH, World J Gastroenterol 2001 7 208 215 11819762 (Pubitemid 32377472)
3. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Bruix J, Llovet JM, Hepatology 2002 35 519 524 10.1053/jhep.2002.32089 11870363 (Pubitemid 34183954)
4. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Gebo KA, Chander G, Jenckes MW, Ghanem KG, Herlong HF, Torbenson MS, El-Kamary SS, Bass EB, Hepatology 2002 36 84 S92 12407580
5. Management of hepatocellular carcinoma. Bruix J, Sherman M, Hepatology 2005 42 1208 1236 10.1002/hep.20933 16250051 (Pubitemid 43112690)
6. Alphafetoprotein: an obituary. Sherman M, J Hepatol 2001 34 603 605 10.1016/S0168-8278(01)00025-3 11394662 (Pubitemid 32328519)
7. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Daniele B, Bencivenga A, Megna AS, Tinessa V, Gastroenterology 2004 127 108 S112 10.1053/j.gastro.2004.09.023 15508073 (Pubitemid 39423377)
8. Hepatocellular carcinomas <2cm in diameter complicating cirrhosis: ultrasound and clinical features in 153 consecutive patients. Rapaccini GL, Pompili M, Caturelli E, Covino M, Lippi ME, Beccaria S, Cedrone A, Riccardi L, Siena DA, Gasbarrini G, Liver Int 2004 24 124 130 10.1111/j.1478-3231.2004.0903. x 15078476 (Pubitemid 38584998)
9. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S, Hepatology 1994 19 61 66 10.1002/hep.1840190111 7506227
10. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. Ishii M, Gama H, Chida N, Ueno Y, Shinzawa H, Takagi T, Toyota T, Takahashi T, Kasukawa R, Am J Gastroenterol 2000 95 1036 1040 10763956 (Pubitemid 30196743)
11. Tissue proteomics for cancer biomarker development: laser microdissection and 2D-DIGE. Kondo T, BMB Rep 2008 41 626 634 10.5483/BMBRep.2008.41.9.626 18823585
12. Proteomics: recent applications and new technologies. Elrick MM, Walgren JL, Mitchell MD, Thompson DC, Basic Clin Pharmacol Toxicol 2006 98 432 441 10.1111/j.1742-7843.2006.pto-391.x 16635100
13. Hepatocellular carcinoma: diagnosis and treatment. Befeler AS, Di Bisceglie AM, Gastroenterology 2002 122 1609 1619 10.1053/gast.2002.33411 12016426 (Pubitemid 34533556)
14. Hepatocellular carcinoma. Llovet JM, Burroughs A, Bruix J, Lancet 2003 362 1907 1917 10.1016/S0140-6736(03)14964-1 14667750 (Pubitemid 37518510)
15. Objective evaluation of data in screening for disease. Sasse EA, Clin Chim Acta 2002 315 17 30 10.1016/S0009-8981(01)00710-0 11728407 (Pubitemid 33145245)
16. Heat-shock protein 27: a potential biomarker for hepatocellular carcinoma identified by serum proteome analysis. Feng JT, Liu YK, Song HY, Dai Z, Qin LX, Almofti MR, Fang CY, Lu HJ, Yang PY, Tang ZY, Proteomics 2005 5 4581 4588 10.1002/pmic.200401309 16240287 (Pubitemid 41739935)
17. Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence. Yi X, Luk JM, Lee NP, Peng J, Leng X, Guan XY, Lau GK, Beretta L, Fan ST, Mol Cell Proteomics 2008 7 315 325 17934217 (Pubitemid 351298446)
18. The K nuclear shuttling domain: a novel signal for nuclear import and nuclear export in the hnRNP K protein. Michael WM, Eder PS, Dreyfuss G, EMBO J 1997 16 3587 3598 10.1093/emboj/16.12.3587 9218800 (Pubitemid 27250052)
19. The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression. Carpenter B, MacKay C, Alnabulsi A, MacKay M, Telfer C, Melvin WT, Murray GI, Biochim Biophys Acta 2006 1765 85 100 16378690
20. Cellular nucleic acid binding protein regulates the CT element of the human c-myc protooncogene. Michelotti EF, Tomonaga T, Krutzsch H, Levens D, J Biol Chem 1995 270 9494 9499 10.1074/jbc.270.16.9494 7721877
21. Unrestraining genetic processes with a protein-DNA hinge. Tomonaga T, Michelotti GA, Libutti D, Uy A, Sauer B, Levens D, Mol Cell 1998 1 759 764 10.1016/S1097-2765(00)80075-1 9660959 (Pubitemid 128379253)
22. hnRNP K: an HDM2 target and transcriptional coactivator of p53 in response to DNA damage. Moumen A, Masterson P, O'Connor MJ, Jackson SP, Cell 2005 123 1065 1078 10.1016/j.cell.2005.09.032 16360036 (Pubitemid 41785421)
23. Host heterogeneous ribonucleoprotein K (hnRNP K) as a potential target to suppress hepatitis B virus replication. Ng LF, Chan M, Chan SH, Cheng PC, Leung EH, Chen WN, Ren EC, PLoS Med 2005 2 163 10.1371/journal.pmed.0020163 16033304 (Pubitemid 46179278)
24. Nuclear shift of hnRNP K protein in neoplasms and other states of enhanced cell proliferation. Ostrowski J, Bomsztyk K, Br J Cancer 2003 89 1493 1501 10.1038/sj.bjc.6601250 14562022 (Pubitemid 37386605)
25. Hepatitis C virus core protein interacts with heterogeneous nuclear ribonucleoprotein K. Hsieh TY, Matsumoto M, Chou HC, Schneider R, Hwang SB, Lee AS, Lai MM, J Biol Chem 1998 273 17651 17659 10.1074/jbc.273.28.17651 9651361 (Pubitemid 28355103)
26. Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer. Barboro P, Repaci E, Rubagotti A, Salvi S, Boccardo S, Spina B, Truini M, Introini C, Puppo P, Ferrari N, Carmignani G, Boccardo F, Balbi C, Br J Cancer 2009 100 1608 1616 10.1038/sj.bjc.6605057 19401687
27. Increased expression of the heterogeneous nuclear ribonucleoprotein K in pancreatic cancer and its association with the mutant p53. Zhou R, Shanas R, Nelson MA, Bhattacharyya A, Shi J, Int J Cancer 126 395 404
28. Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer. Carpenter B, McKay M, Dundas SR, Lawrie LC, Telfer C, Murray GI, Br J Cancer 2006 95 921 927 10.1038/sj.bjc.6603349 16953238 (Pubitemid 44498109)